Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to "Hold" at StockNews.com

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Thursday.

A number of other equities analysts have also commented on JAZZ. Robert W. Baird cut their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Morgan Stanley lowered their price objective on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Finally, HC Wainwright lifted their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a report on Monday, March 10th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $182.79.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $106.59 on Thursday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a 1-year low of $95.49 and a 1-year high of $148.06. The firm has a market cap of $6.57 billion, a price-to-earnings ratio of 15.01, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. The firm's fifty day moving average price is $116.92 and its 200 day moving average price is $122.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same period in the previous year, the company posted $2.68 EPS. The business's quarterly revenue was down .5% on a year-over-year basis. On average, sell-side analysts expect that Jazz Pharmaceuticals will post 16.96 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Seamus Mulligan acquired 100,000 shares of the business's stock in a transaction on Friday, May 9th. The shares were acquired at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the completion of the acquisition, the director now owns 100,000 shares in the company, valued at $9,826,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. The trade was a 10.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,236 shares of company stock worth $3,956,190. Insiders own 4.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CreativeOne Wealth LLC purchased a new stake in Jazz Pharmaceuticals during the first quarter worth $202,000. Campbell & CO Investment Adviser LLC purchased a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $3,674,000. Systematic Financial Management LP increased its position in shares of Jazz Pharmaceuticals by 2.8% during the 1st quarter. Systematic Financial Management LP now owns 386,903 shares of the specialty pharmaceutical company's stock worth $48,034,000 after purchasing an additional 10,590 shares during the last quarter. Jump Financial LLC acquired a new position in Jazz Pharmaceuticals during the 1st quarter worth about $550,000. Finally, SVB Wealth LLC purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $36,000. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.